Welcome to our dedicated page for Qualigen Therapeutics news (Ticker: QLGN), a resource for investors and traders seeking the latest updates and insights on Qualigen Therapeutics stock.
Qualigen Therapeutics, Inc. (NASDAQ: QLGN), now operating under the name AIxCrypto Holdings, Inc. with the ticker AIXC, generates news that spans both biotechnology and digital asset markets. Company press releases and SEC reports describe a transition from a clinical-stage oncology and infectious disease drug developer into a cross-disciplinary enterprise focused on decentralized AI, Web3 asset infrastructure, and intelligent trading systems.
News items for QLGN and AIXC include updates on strategic financings, such as the $41 million PIPE transaction led by Faraday Future Intelligent Electric Inc., which resulted in majority beneficial ownership and new governance arrangements. Coverage also highlights Nasdaq listing and compliance communications, including notices related to stockholder equity requirements and shareholder approval rules, and the company’s responses through private placements and stockholder meetings.
On the technology and crypto side, the company issues detailed announcements about the launch and evolution of its C10 Cryptocurrency Asset Treasury, which follows an 80% passive and 20% active allocation strategy to top cryptocurrencies, and about partnerships supporting this strategy, such as its agreement with BitGo for digital asset custody and liquidity access. Additional news focuses on the BesTrade DeAI Agent, C10 Index and treasury products, potential C10 ETF concepts, and ecosystem tokens like a potential C10 stablecoin and EAI + Crypto RWA dual-bridge products.
Biotech-focused updates continue to appear as well, including patent grants for QN-302 across numerous countries and descriptions of the company’s ongoing QN-302 clinical trial and Pan-RAS preclinical program. Governance and leadership changes, including new board appointments and executive roles associated with Faraday Future, are also recurring themes. Investors and observers can use this news stream to follow the company’s dual-track evolution in therapeutics and AI × Web3 initiatives.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Qualigen Therapeutics reported that it received a notification from Nasdaq regarding its failure to file the Annual Report on Form 10-K for the year ending December 31, 2022, as mandated by Nasdaq Rules. The delay in the filing, due to additional information required for the company’s acquisition of a majority interest in NanoSynex, Ltd, resulted in the company filing a Notification of Late Filing on Form 12b-25. While this notification does not immediately affect the Nasdaq listing, failure to regain compliance may lead to delisting. Qualigen is working to file the Form 10-K by June 20, 2023, which would help avoid submitting a formal compliance plan.
Qualigen Therapeutics (Nasdaq: QLGN) announced significant findings from its QN-302 program presented at the AACR Annual Meeting 2023. The data highlighted QN-302's potential as a treatment for pancreatic cancer, showing 10-fold greater potency compared to existing therapies like gemcitabine in resistant cell lines. Doctor Tariq Arshad stated that these results support their goal to submit an IND application to the FDA to initiate Phase 1 trials for QN-302. The research demonstrated that QN-302 targets the S100P gene, a promising biomarker for therapy tracking, and confirmed anti-tumor activity in various in vivo models.
QN-302 has already been granted Orphan Drug Designation by the FDA, underlining its potential as a novel treatment strategy against cancers characterized by G4 structures.
Qualigen Therapeutics (Nasdaq: QLGN) has presented promising in vivo efficacy data regarding its QN-247 program at the American Association for Cancer Research (AACR) Annual Meeting 2023. This data suggests that QN-247 could serve as an effective nano-immunotherapy against triple negative breast cancer. The study showed significant reductions in tumor volumes without toxic side effects.
QN-247, a nucleolin-targeted oligonucleotide conjugate, demonstrates potential against various malignancies, including acute myeloid leukemia and glioblastoma. The company is actively seeking partners to advance the development of QN-247. Qualigen's broader portfolio includes diagnostics and other investigational compounds targeting different cancer types.
Qualigen Therapeutics announces the grant of U.S. Patent No. 11,560,380 for its lead oncology drug candidate, QN-302. This patent protects the composition of matter for QN-302, a small molecule selective transcription inhibitor targeting G4 complexes in solid tumors, including pancreatic cancer, with exclusivity until 2040. The company also received a Notice of Intent for a similar patent in the E.U. CEO Michael Poirier emphasized the importance of this patent for QN-302's development, and the company is preparing to submit an Investigational New Drug (IND) application soon. QN-302 has already received Orphan Drug Designation from the FDA for pancreatic cancer.